TY - JOUR
T1 - Isolation, identification and pharmacokinetic analysis of fructosyl puerarins from enzymatic glycosylation
AU - Wu, Xueming
AU - Chu, Jianlin
AU - Xu, Tingting
AU - He, Bingfang
PY - 2013/9/5
Y1 - 2013/9/5
N2 - A method of using high-speed counter-current chromatography (HSCCC) was established for preparative isolation and purification of puerarin glycosides from the crude sample after enzymatic glycosylation of puerarin. Four fructosyl puerarins were successfully purified for the first time by HSCCC with a two-phase-solvent system composed of n-butanol-acetic acid-water (4:1.5:6, v/v/v). A total of 5mg of puerarin (1), 20mg of ß-d-fructofuranosyl-(2?6)-puerarin (2), 41mg of ß-d-difructofuranosyl-(2?6)-puerarin (3), 18mg of ß-d-trifructofuranosyl-(2?6)-puerarin (4) and 15mg ß-d-tetrafructofuranosyl-(2?6)-puerarin (5) were obtained in one-step separation from 100mg of the crude sample with purities of 98.5%, 98.3%, 98.9%, 97.8%, 97.5% and 97.2%, respectively. Among them, compounds 2-5 are novel compounds, and their chemical structures were identified by HRMS, 1H NMR, 13C NMR and 2D NMR. Pharmacokinetic analysis showed that ß-d-fructofuranosyl-(2?6)-puerarin (2) was able to maintain higher plasma concentrations and have a longer mean residence time in the blood than puerarin.
AB - A method of using high-speed counter-current chromatography (HSCCC) was established for preparative isolation and purification of puerarin glycosides from the crude sample after enzymatic glycosylation of puerarin. Four fructosyl puerarins were successfully purified for the first time by HSCCC with a two-phase-solvent system composed of n-butanol-acetic acid-water (4:1.5:6, v/v/v). A total of 5mg of puerarin (1), 20mg of ß-d-fructofuranosyl-(2?6)-puerarin (2), 41mg of ß-d-difructofuranosyl-(2?6)-puerarin (3), 18mg of ß-d-trifructofuranosyl-(2?6)-puerarin (4) and 15mg ß-d-tetrafructofuranosyl-(2?6)-puerarin (5) were obtained in one-step separation from 100mg of the crude sample with purities of 98.5%, 98.3%, 98.9%, 97.8%, 97.5% and 97.2%, respectively. Among them, compounds 2-5 are novel compounds, and their chemical structures were identified by HRMS, 1H NMR, 13C NMR and 2D NMR. Pharmacokinetic analysis showed that ß-d-fructofuranosyl-(2?6)-puerarin (2) was able to maintain higher plasma concentrations and have a longer mean residence time in the blood than puerarin.
KW - Biotransformation
KW - Fructosyl puerarins
KW - High-speed counter-current chromatography
KW - Pharmacokinetic
UR - http://www.scopus.com/inward/record.url?scp=84882750701&partnerID=8YFLogxK
U2 - 10.1016/j.jchromb.2013.07.012
DO - 10.1016/j.jchromb.2013.07.012
M3 - 文章
AN - SCOPUS:84882750701
SN - 1570-0232
VL - 935
SP - 70
EP - 74
JO - Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences
JF - Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences
ER -